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AtherosclerosisAbstract Background: Systemic sclerosis (SSc) is a rare multi-system autoimmune disease charac-
terized by vascular abnormalities with an increased prevalence of macrovascular disease.
Aim of the work: To evaluate macro-vascular disease (atherosclerosis) in SSc patients and deter-
mine its relation to the disease activity and severity.
Patients and methods: Twenty-ﬁve SSc patients and 20 matched controls were included. The
modiﬁed Rodnan skin score (mRss) and disease severity by Medsger’s severity score were assessed.
Carotid intima-media thickness (IMT) and ﬂow mediated vasodilatation (FMD) of the brachial
artery were measured. Traditional vascular risk factors were assessed by thorough history taking
and laboratory investigations.
Results: The age of the patients ranged from 15 to 60 years and they were 22 females and 3
males. 15 had limited and 10 diffuse cutaneous SSc. All SSc patients had an increased IMT
(1.24 ± 0.29 mm) which was normal in the control subjects (0.77 ± 0.09 mm) (p< 0.0001). SSc
patients had signiﬁcantly lower HDL, thickened IMT and lower FMD than controls (p= 0.005,
p< 0.0001 and p< 0.0001 respectively). The younger age of disease onset was signiﬁcantly asso-
ciated with more FMD impairment (r= 0.4, p= 0.04) and Medsger’s severity score (r= 0.5,
p= 0.009). The mRss and Medsger’s severity score signiﬁcantly correlated with the IMT
(r= 0.84, p= 0.01 and r= 0.56, p= 0.003 respectively). A signiﬁcant negative correlation was
found between FMD and IMT (r= 0.77, p< 0.0001). Medsger’s severity score signiﬁcantly cor-
related with FMD (r= 0.44, p= 0.02).district,
196 A.B. El-Din et al.Conclusion: SSc is associated with an increased risk of atherosclerosis when compared to age and
sex-matched controls. Determinants of this include; younger age of disease onset and more sever
disease and low levels of HDL.
 2015 The Authors. Publishing services provided by Elsevier B.V. on behalf of Egyptian Society of
Rheumatic Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Systemic sclerosis (SSc) is a rare multi-system autoimmune dis-
ease of multifactorial origin that is characterized by vascular
abnormalities and diffuse ﬁbrosis in the skin and joints, and
by progressive involvement of the internal organs [1]. SSc is
about eight times more common among women than men
[2]. It is most common in the third to ﬁfth decades of life
and is rare in children [3].
The most common initial symptoms and signs are vascular,
such as Raynaud’s phenomenon, which is often long-lasting, as
well as insidious swelling of the distal extremities with puffy
ﬁngers, followed by gradual thickening of the skin of the face
and ﬁngers with late skin ulcers. On the basis of the extent of
skin involvement, SSc can be categorized into two forms: dif-
fuse and limited cutaneous SSc [4].
Atherosclerosis is considered as a chronic inﬂammatory dis-
ease where monocytes, macrophages and T-cells as well as
autoantibodies, autoantigens and cytokines play a role. It is
considered the leading cause of death in developed countries.
Atherosclerosis affects large and medium-sized arteries and
can cause coronary heart disease, stroke and peripheral vascu-
lar disease [5].
The vasculopathy of SSc typically affects the small arteries
and capillaries, but an increased prevalence of macrovascular
disease has also been suggested [6]. Subclinical coronary artery
abnormalities were reported in Egyptian SSc patients [7]. The
pathophysiology of SSc involves endothelial and vascular
damage and the activation of ﬁbroblasts; consequently, colla-
gen and other extracellular matrix proteins are overproduced
in almost all tissues. The innate and adaptive immune systems
are activated in the perivascular areas, releasing their compo-
nent immunological mediators such as cytokines and growth
factors (transforming growth factor-b, platelet-derived growth
factor, endothelin-1) and extensive ﬁbrosis in the dermal and
subcutaneous layers develops [8]. In other studies on Egyptian
SSc patients, increased cluster of differentiation 36 (throm-
bospondin receptor) was considered as a marker of vascular
involvement and severity [9] and the serum cartilage oligomeric
matrix protein was signiﬁcantly increased [10].
Thus, there is both vasospasm in the small vessels, and
endothelial dysfunction. Such endothelial dysfunction has
been shown to predict future cardiovascular (CV) events in
many clinical situations via the development of large vessel
(macrovascular) atherosclerosis over time [11]. Furthermore,
the novel non-traditional CV risk factors for atherosclerosis
are also present in SSc, such as increased lipoprotein (a), oxi-
dized LDL, adrenomedullin and inﬂammation [12]. Moreover,
markers of vascular damage like Von Willebrand Factor
(vWF) and increased levels of vascular adhesion molecules
are present in SSc which are also linked to atherosclerosis
[13]. In this regard, it is of great importance to delineate the
macrovascular disease (atherosclerosis) in SSc.The present study aimed at evaluating the macro-vascular
disease (atherosclerosis) in patients with SSc and determining
its relation to the disease activity and severity.
2. Patients and methods
2.1. Clinical evaluation
The present case control study was carried out on 25 SSc
patients who attended the rheumatology outpatient clinics of
Ain Shams and Cairo University hospitals. Patients were
recruited from October 2013 to November 2014. Twenty
healthy volunteers matching in age and sex served as a control
group. Written consent was obtained from every patient and
control which was approved by Ain Shams medical Ethical
Committee.
Systemic sclerosis (SSc) was diagnosed according to the cri-
teria of the American College of Rheumatology [14] and was
classiﬁed as limited or diffuse cutaneous subtypes according
to the criteria of Le Roy et al. [15]. Patients were subjected
to full medical history taking with special emphasis on disease
duration, body mass index (BMI) calculation and thorough
clinical examination. The severity and extent of skin sclerosis
were assessed using the modiﬁed Rodnan skin score (mRss)
[16]. Disease severity was assessed by Medsger’s severity score
of 9 organs [17].
2.2. Laboratory assessment
Venous blood (8 ml) was withdrawn from each patient where,
ﬁve ml was placed in EDTA tube for performing complete
blood count (CBC) and erythrocyte sedimentation rate
(ESR) and three ml of blood was collected in plain vacutainers
for analysis of anti-nuclear antibody (ANA) and anti-double
stranded deoxyribonucleic acid (anti-dsDNA). Serum samples
were stored at 20 C until time of assay. CBC was done using
Coulter counter (T660), ESR was done by the Westergren
method. ANA was done using indirect immunoﬂuorescence
assay using IMMCO Diagnostics, USA (ANA on Hep-2 sub-
strate). As well, lipid proﬁle was assessed; total cholesterol,
triglycerides, high density lipoprotein (HDL) and low density
lipoprotein (LDL). The C-reactive protein (CRP) and serum
insulin levels were also assessed in patients and control.
2.3. Radiological assessment
2.3.1. Carotid duplex
The patients were examined using Voluson S8 (GE Health
care) Ultrasonography apparatus with color Doppler and high
resolution 12 MHZ linear array transducer. Common carotid,
the carotid bulbs, the proximal internal and external carotid
arteries were evaluated by gray scale. The patients were placed
Table 1 Descriptive data of the systemic sclerosis patients.
Variable Systemic Sclerosis (SSc) patients (n= 25)
Median (Range) 25th–75th
percentile
BMI 23.1 (16–38.6) 21.3–29
Laboratory investigations
ESR (mm/1st hr) 30 (7–55) 21.5–45
CRP (mg/L) 5.2 (0.25–25.5) 1.7–7.05
Hemoglobin (g/dl) 12.1 (10.1–14.7) 11.3–13.8
TLC (103/mm3) 7.7 (4.4–13.7) 5.5–9
Platelets (103/mm3) 306 (150–605) 249.5–388
ALT (IU/L) 16 (8–154) 11.5–25
AST (IU/L) 24 (15–159) 19.5–29
s Creatinine (mg/dl) 0.6 (0.3–1.4) 0.45–0.8
Cholesterol (mg/dl) 185 (86–359) 152.5–200.5
Triglycerides (mg/dl) 127 (26–326) 71.5–192.8
Insulin (IU/ml) 2.4 (0.7–20.8) 1.1–4.7
SSc scores
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away from the side being examined. The common carotid
artery was scanned longitudinally, and the IMT measurement
was taken as the average of 6 measurements throughout the
length of the artery, 3 each from the right and left common
carotid arteries as follows; [1 cm from its origin, mid part
and 1 cm away from the bulb] as the maximum distance
between the intima–lumen and adventitia–media interfaces in
areas without carotid plaque. Axial scanning was also per-
formed searching for the presence of any carotid plaques and
their dimensions were measured meticulously. A cut off value
of 0.9 mm was taken for IMT, patients who had IMT above
this value were considered to have atherosclerosis [18].
2.3.2. Flow mediated vasodilatation [FMD] of the brachial
artery
2.3.2.1. Patient preparation. All patients were studied in the
morning between 8 and 11 am after 8 hours over-night fasting
including tobacco and caffeine with any vasoactive medica-
tions withheld for at least four half lives and no exercise
allowed. Before initiating the FMD scan, all patients were rest-
ing in a quiet temperature-controlled room in supine position
with the right upper limb resting in a comfortable cradle sup-
port. Arterial blood pressure was measured in all subjects to
determine the peak systolic blood pressure for each patient.
2.3.2.2. Image acquisition. FMD was assessed using Voluson
S8 (GE Health care) Ultrasonography apparatus with color
Doppler and high resolution 12 MHZ linear array transducer
with timing of each image frame according to the cardiac cycle
as measurement of the brachial artery dimension was taken at
the minimum diameter of the vessel during diastole. The bra-
chial artery is longitudinally identiﬁed 5 cm proximal to the
antecubital fossa along the medial surface of the arm and an
arterial segment that shows clear anterior and posterior
lumen-intima interface. The average of three measurements
of maximum vessel diameter at rest (D1) is obtained. A sphyg-
momanometer cuff is placed at the forearm 5 cm distal to the
antecubital fossa and Inﬂation of the cuff 50 mm HG above
the systolic blood pressure of the patient for 5 min is done to
induce local ischemia after which the cuff is deﬂated and reac-
tive hyperemia is obtained. The average of three new measure-
ments of the maximum vessel diameter is taken with the same
technique previously described after 45 till 60 s after cuff deﬂa-
tion (D2) [19]. Flow mediated vasodilatation percentage was
calculated using the following formula;
FMD%¼ post deflation diameterðD2Þ resting diameterðD1Þ
Resting diameterðD1Þ
 100
mRss 16 (3–40) 14–26.5
Medsgers severity 9 (0–15) 7–11
Vascular ultrasonography
Carotid IMT (mm) 1.3 (0.7–1.7) 1–1.5
FMD (%) 6.9 (2.5–25) 4.9–9.9
BMI: body mass index, ESR: erythrocyte sedimentation rate, CRP:
C-reactive protein, TLC: total leukocytic count, ALT: alanine
transaminase, AST: aspartate transaminase, s: serum, mRss:
modiﬁed rodnan skin score, IMT: intima media thickness, FMD:
ﬂow mediated dilatation.2.3.3. Statistical methods
IBM SPSS statistics (V. 22.0, IBM Corp., USA, 2013) was
used for data analysis. Date was expressed as Median, range
and percentiles for quantitative non-parametric measures in
addition to both number and percentage for categorized data.
Comparison between two independent groups for non-
parametric data was done using Wilcoxon Rank Sum test.
Ranked Spearman correlation test was used to study the pos-
sible association between each two variables among eachgroup for non-parametric data. Chi-square test was performed
to study the association between each 2 variables or compar-
ison between 2 independent groups as regards the categorized
data. The probability of error 60.05 was considered signiﬁ-
cant, while 60.01 was considered highly signiﬁcant.
3. Results
The present study included 25 patients with systemic sclerosis
(SSc) they were 3 males (12%) and 22 females (88%), with an
age ranging from 15 to 60 years, and disease duration ranged
from 0.7 to 20 years. Twenty age and sex matched healthy
volunteers served as controls with age ranging from 19 to
44 years; p= 0.75 and M:F was 1:8. The BMI was also com-
parable (p= 0.2). Other descriptive data of the patients group
are displayed in Table 1. Twenty-three patients (92%) had pos-
itive ANA; of which 15 (60%) were speckled, 5 (20%) homoge-
nous and 3 (12%) nucleolar. All the SSc patients had an
increased IMT (1.24 ± 0.29 mm) while it was of normal thick-
ness in all the control (0.77 ± 0.09 mm) (p< 0.0001) (Fig. 1).
On comparing SSc patients and controls as regards deter-
minants of atherosclerosis, the patients had a signiﬁcantly
lower HDL (p= 0.005), thickened IMT (p< 0.0001) and
lower FMD (p< 0.0001). Other factors such as serum insulin,
CRP, Cholesterol, triglycerides and LDL were comparable
(Table 2).
As regard clinical presentation, 15 patients (60%) had lim-
ited scleroderma, while 10 (40%) had diffuse systemic sclerosis.
Pulmonary hypertension was evident only in 4 patients (16%)
while 13 patients (52%) had interstitial pulmonary ﬁbrosis
Figure 1 Common carotid artery (CCA) doppler ultrasound of a control with normal intima-media thickness (IMT) (0.03 cm) (Left) and
a systemic sclerosis patient with increased IMT (0.17 cm) with diffuse ﬁne intimal calciﬁcation (Right).
Table 2 Comparison between systemic sclerosis patients and control as regards determinants of atherosclerosis, intima media
thickness and ﬂow mediated dilatation.
Determinants median (range) SSc patients (n= 25) Control (n= 20) Z p
BMI 23.1 (16–38.6) 25.05 (21.9–36.1) 1.28 0.2
Cholesterol (mg/dl) 185 (86–359) 191.5 (159–259) 1.05 0.29
Triglycerides (mg/dl) 127 (26–326) 116 (73–149) 0.31 0.75
HDL (mg/dl) 29 (2–94) 51 (24–89) 2.84 0.005
LDL (mg/dl) 127 (40–256) 115 (98–204) 1.12 0.26
Insulin (IU/ml) 2.4 (0.7–20.8) 3.6 (0.9–11.8) 1.41 0.16
CRP (mg/L) 5.2 (0.25–25.5) 2.55 (0.3–10.7) 1.50 0.13
Carotid IMT (mm) 1.3 (0.7–1.7) 0.8 (0.6–0.9) 4.95 0.0001
FMD (%) 6.9 (2.5–25) 13 (11–16) 4.25 0.0001
BMI: body mass index, HDL: high density lipoprotein, LDL: low density lipoprotein, CRP: C-reactive protein, IMT: intima media thickness,
FMD: ﬂow mediated dilatation.
Table 3 Clinical presentation of systemic sclerosis (SSc)
patients.
Presentation n (%) SSc patients (n= 25)
Limited SSc 15 (60)
Diﬀuse SSc 10 (40)
Pulmonary hypertension 4 (16)
Interstitial pulmonary ﬁbrosis 13 (52)
Raynaud’s phenomenon 25 (100)
Skin tightness 8 (32)
Arthralgia 3 (12)
Muscle weakness 1 (4)
Hypertension 4 (16)
Diabetes mellitus 1 (4)
SSc: Systemic sclerosis.
Table 4 Correlation between personal demographic data and
parameters of vascular impairment and disease severity in
systemic sclerosis (SSc) patients.
Parameter r (p) Systemic sclerosis (SSc) patients (n= 25)
Age Age at onset BMI
Carotid IMT 0.3 (0.2) 0.4 (0.07) 0.2 (0.4)
FMD 0.3 (0.1) 0.4 (0.04) 0.1 (0.7)
mRss 0.1 (0.4) 0.2 (0.3) 0.4 (0.04)
Medsger’s severity 0.5 (0.01) 0.5 (0.009) 0.1 (0.7)
BMI: body mass index, IMT: intima media thickness, FMD: ﬂow
mediated dilation, mRss: modiﬁed Rodnan skin score. Bold values
are signiﬁcant at p< 0.05.
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When patients with limited scleroderma were compared with
those with diffuse disease as regards determinants of
atherosclerosis, only BMI was signiﬁcantly lower in patients
with diffuse disease (p= 0.015).
A younger age of disease onset was associated with more
FMD impairment and more severe disease. As well, patientswith lower BMI suffered from more severe disease. Correlation
of the demographic parameters with the vascular impairment
and disease severity parameters are shown in Table 4. Modi-
ﬁed Rodnan skin score (mRss) and Medsger’s severity score
signiﬁcantly correlated with the carotid IMT (r= 0.84,
p= 0.01 and r= 0.56, p= 0.003 respectively). A signiﬁcant
negative correlation was found between FMD and carotid
IMT showing that patients with increased IMT had more
impaired FMD (r= 0.77, p< 0.0001) (Fig. 2). Medsger’s
Figure 2 Correlation of carotid intima media thickness (IMT)
with (a) skin disease assessed by modiﬁed Rodnan skin score
(mRss), (b) Medsger’s severity score, (c) ﬂow mediated vasodi-
latation (FMD) in systemic sclerosis patients.
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p= 0.02). The correlation was insigniﬁcant between the mRss
with the FMD (r= 0.34, p= 0.09).
4. Discussion
Systemic sclerosis (SSc) is a chronic disease of unknown etiol-
ogy, characterized by enhanced ﬁbrosis, and microvascular
abnormalities [4]. Patients with systemic inﬂammatory condi-
tions such as rheumatoid arthritis (RA), systemic lupus erythe-
matosus (SLE) and Behc¸et’s disease have been shown to
develop premature and accelerated atherosclerosis [20–24].
Although microvascular disease is a hallmark of SSc, an ongo-
ing debate exists regarding the presence and extent of
macrovascular diseases and the presence of accelerated
atherosclerosis in SSc patients [25].Our study was conducted on 25 patients with systemic
sclerosis (SSc), 60% of the patients had limited scleroderma
while 40% had diffuse systemic sclerosis, and we detected
pulmonary hypertension in 16% and evidence of IPF in 52%
of our studied (SSc) patients. Turiel et al. [26] studied 20
patients with systemic sclerosis they found that all of the
patients had diffuse SSc, and none of them showed lung
involvement or pulmonary hypertension. Also, only 35% of
their patients had positive Raynaud’s phenomenon while it
was positive in 100% of our studied cases.
In the present study, comparison between cases and con-
trols as regard determinants of atherosclerosis revealed that
the SSc patients had lower level of HDL, and there were no
differences in BMI, CRP, and serum insulin level between
two groups. These results partially agree with the results of
Zeng et al., who found no differences in lipid proﬁle (including
total cholesterol, triglyceride, LDL-C HDL-C) between their
studied cases of SSc and the controls but, they recorded that
the SSc patients had higher level of Hs-CRP and lower BMI
(p< 0.01) than control subjects. [27] Also, Colaci et al.
recorded a signiﬁcantly lower BMI among their studied cases
of SSc than the controls (22.3 ± 3.6 vs 25 ± 2.7; p= 0.006)
[28].
Cypiene et al. studying a small series of 17 SSc patients
compared to 34 healthy controls found that only triglyceride
concentration was signiﬁcantly higher in SSc patients than in
controls [29]. As regards the ANA it was positive in 92%
ð23 n 25Þ of our patients while Colaci et al. recorded that it
was positive only in 14.3% ð5 n 35Þ of their cases [28].
Involvement of the microvasculature is one of the earliest
features of SSc, preceding and potentially contributing via
tissue ischemia to the wide spread ﬁbrosis characteristic of this
condition. These microvascular abnormalities contribute to the
pathogenesis of pulmonary arterial hypertension (PAH),
scleroderma renal crisis, Raynaud’s phenomenon, and digital
ulceration [25]. Although macrovascular disease was not
originally considered a feature of SSc, multiple studies have
revealed an increased prevalence of large-vessel disease of the
upper and lower limbs in patients with SSc [30,31]. Accelerated
atherosclerosis has been also described in some patients with
SSc [32]. In another study on Egyptian SSc patients, there
was an increased risk of subclinical atherosclerosis and
peripheral arterial disease. Increased systolic blood pressure,
dyslipidemia, long disease duration and older age were
possible risk factors [33].
Non-invasive surrogate markers of early atherosclerosis
have been developed to allow the early detection of atheroscle-
rosis before overt disease. High-resolution ultrasonographic
measurement of the carotid IMT is one such method [34]. In
this study we found highly signiﬁcant difference in the carotid
IMT between SSc patients and controls (p< 0.001), suggest-
ing an increased prevalence of early atherosclerotic macrovas-
cular disease in SSc. Also, our results revealed that the IMT
signiﬁcantly correlated with the severity of skin disease (mRss)
and higher Medsger’s severity score. This ﬁnding occurred in
accordance with Turiel and colleagues [26], Kaloudi and col-
leagues [35], and Bartoli and colleagues [36] who found
strongly increased carotid IMT in SSc patients compared with
controls. In another study on Egyptian SSc patients, the IMT
was signiﬁcantly increased compared to the control [33]. On
the other hand our results are in disagreement with those of
Cheng and colleagues [37] and Szucs and colleagues [38],
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pared with those of controls. These discrepancies between
studies in the presence of early atherosclerosis as measured
by common carotid IMT in SSc patients might be explained
by methodological differences, such as patients included in
the study and co-morbidity.
Endothelial dysfunction has been postulated to represent
an initial step in the atherogenesis of atherosclerosis in the gen-
eral population [39]. Flow-mediated vasodilatation (FMD) is
currently the most widely used method for assessment of vas-
cular reactivity due to its non-invasive nature [40]. In the pre-
sent study there was a highly signiﬁcant difference in the FMD
between patients with SSc and healthy controls (p< 0.001).
These results are in accordance with the results of Szucs and
colleagues [38], who found the FMD was signiﬁcantly lower
(4.82 ± 3.76%) in SSc patients in comparison with the con-
trols (8.86 ± 13.56%) (p< 0.001). Also, Au and colleagues
recorded in their meta-analysis of FMD studies a signiﬁcantly
lower FMD in SSc when compared to controls with a mean
difference of 3.01% [41]. On the other hand Andersen
et al. [42] found similar FMD in 24 SSc patients compared
with controls. However, their patient population also included
mixed connective tissue disease (MCTD) patients. Here we
studied solely SSc patients.
In this study we found that FMD impairment signiﬁcantly
correlated with younger age of disease onset and more severe
disease. Further correlation between FMD and carotid IMD
showed that patients with more thickening of intima media
of carotids had much more impaired FMD (r= 0.77 and
p< 0.0001). Szucs and colleagues [38] recorded that neither
FMD nor nitroglycerin-mediated dilation (NMD) correlated
with disease duration suggesting that the early impairment of
FMD is associated with SSc-speciﬁc early events and not with
long-term disease.
In the present study we found that there was a signiﬁcant
correlation between both the severity of skin disease (mRss)
and higher Medsger’s severity score and carotid IMT, but only
the Medsger’s severity score signiﬁcantly correlated with
FMD. To our knowledge, there are no previously available
recorded correlations between IMT and FMD and Medsger’s
severity score or the severity of the skin disease (mRss).
In conclusion, SSc is associated with increased atherosclero-
sis and its determinants include younger age of disease onset,
more severe disease and low levels of HDL. Further research
in the mechanism of increased risk of atherosclerosis in SSc
and on a larger number of patients is warranted as its recogni-
tion could have important clinical ramiﬁcations.
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